Frank Verhoeven1, Clément Prati2, Céline Demougeot3, Daniel Wendling4. 1. Service de rhumatologie, CHRU de Besanço, 25030 Besançon cedex, France; EA 4267 « PEPITE », université de Bourgogne Franche-Comté, 25000 Besançon, France. Electronic address: fverhoeven@chu-besancon.fr. 2. Service de rhumatologie, CHRU de Besanço, 25030 Besançon cedex, France; EA 4267 « PEPITE », université de Bourgogne Franche-Comté, 25000 Besançon, France. 3. EA 4267 « PEPITE », université de Bourgogne Franche-Comté, 25000 Besançon, France. 4. Service de rhumatologie, CHRU de Besanço, 25030 Besançon cedex, France; EA 4266 «EPILAB », université de Bourgogne Franche-Comté, 25000 Besançon,France.
Abstract
INTRODUCTION: Psoriatic arthritis (PsA) is a chronic inflammatory rheumatism characterized for a long time by a high degree of cardiovascular risk. Chronic inflammation is one of the mechanisms that explain this cardiovascular excess of risk through direct and indirect pathways. In recent years, epidemiological data have changed somewhat since the increasing use of bio-drugs that are effective in reducing this inflammation. The purpose of this review is to assess the current state of cardiovascular morbidity and mortality in PsA and thus to assess the cardiovascular risk in case of PsA. METHOD: We conducted a literature review using Pubmed and Medline databases with the following keywords "Psoriatic Arthritis" AND "cardiovascular" including articles from the last three years. RESULTS: It appears that in case of PsA, there is an increased prevalence of high blood pressure, diabetes, obesity and dyslipidemia, and therefore of metabolic syndrome. Insulin resistance is closely linked to PsA. On the other hand, the data are more contrasted for active smoking. There is also arterial inflammation specific to PsA. Finally, at the therapeutic level, the impact of NSAIDs remains controversial, while methotrexate and bio-drugs are beneficial at the cardiovascular level. CONCLUSION: PsA is characterized by an increase in cardiovascular morbidity in relation with insulin resistance. Current treatments seem to improve this risk with a decrease in cardiovascular mortality in comparison with patients with plaque psoriasis but this requires confirmation in larger prospective studies.
INTRODUCTION:Psoriatic arthritis (PsA) is a chronic inflammatory rheumatism characterized for a long time by a high degree of cardiovascular risk. Chronic inflammation is one of the mechanisms that explain this cardiovascular excess of risk through direct and indirect pathways. In recent years, epidemiological data have changed somewhat since the increasing use of bio-drugs that are effective in reducing this inflammation. The purpose of this review is to assess the current state of cardiovascular morbidity and mortality in PsA and thus to assess the cardiovascular risk in case of PsA. METHOD: We conducted a literature review using Pubmed and Medline databases with the following keywords "Psoriatic Arthritis" AND "cardiovascular" including articles from the last three years. RESULTS: It appears that in case of PsA, there is an increased prevalence of high blood pressure, diabetes, obesity and dyslipidemia, and therefore of metabolic syndrome. Insulin resistance is closely linked to PsA. On the other hand, the data are more contrasted for active smoking. There is also arterial inflammation specific to PsA. Finally, at the therapeutic level, the impact of NSAIDs remains controversial, while methotrexate and bio-drugs are beneficial at the cardiovascular level. CONCLUSION:PsA is characterized by an increase in cardiovascular morbidity in relation with insulin resistance. Current treatments seem to improve this risk with a decrease in cardiovascular mortality in comparison with patients with plaque psoriasis but this requires confirmation in larger prospective studies.
Authors: Yannick Degboé; Richard Koch; Laurent Zabraniecki; Bénédicte Jamard; Guillaume Couture; Jean Bernard Ruidavets; Jean Ferrieres; Adeline Ruyssen-Witrand; Arnaud Constantin Journal: Front Med (Lausanne) Date: 2022-05-19
Authors: Shirley Chiu Wai Chan; Cheong Kay Teo; Philip Hei Li; Kui Kai Lau; Chak Sing Lau; Ho Yin Chung Journal: Ther Adv Musculoskelet Dis Date: 2021-07-27 Impact factor: 5.346
Authors: Andrew Östör; Filip Van den Bosch; Kim Papp; Cecilia Asnal; Ricardo Blanco; Jacob Aelion; Gabriela Alperovich; Wenjing Lu; Zailong Wang; Ahmed M Soliman; Ann Eldred; Lisa Barcomb; Alan Kivitz Journal: Ann Rheum Dis Date: 2021-11-23 Impact factor: 19.103
Authors: Ivan Arias de la Rosa; Maria Dolores López-Montilla; Cristobal Román-Rodríguez; Carlos Pérez-Sánchez; Ignacio Gómez-García; Clementina López-Medina; Maria Lourdes Ladehesa-Pineda; Maria Del Carmen Ábalos-Aguilera; Desiree Ruiz; Alejandra Maria Patiño-Trives; Maria Luque-Tévar; Isabel Añón-Oñate; Maria Jose Pérez-Galán; Rocio Guzmán-Ruiz; Maria M Malagón; Chary López-Pedrera; Alejandro Escudero-Contreras; Eduardo Collantes-Estévez; Nuria Barbarroja Journal: J Intern Med Date: 2022-03-02 Impact factor: 13.068